基本信息
浏览量:26
职业迁徙
个人简介
Professional Profile
Prof. Dr. Elizabeth de Lange has been trained as a chemist, with specialization in Biophysical Chemistry (Groningen University, Groningen, The Netherlands). She obtained her PhD in Pharmacology (Leiden- Academic Center for Drug Research (LACDR), Leiden University, The Netherlands). She got tenure at the LACDR. She currently is Professor on Predictive Pharmacology and the Principal Investigator of the Predictive Pharmacology Group in the Research Division of Systems Biomedicine & Pharmacology of the LACDR.
Research profile
Elizabeth de Lange is concerned with the allocation of resources for the conduct of science towards the goal of best serving the public interest. Also, while she underscores that there is still the need for using animals in drug research, she is concerned about this use, and advocates the use of the Mastermind Research Approach by which knowledge obtained from animals can be condensed and stored in mathematical models.
Elizabeth de Lange has a clearly visible and original personal line of research, initially mostly focused on the CNS, but more and more expanding to other tissues and generic pharmacological research questions, which are specified below. She is one of the few in the world that is able to perform and bridge advanced experiments and analytical techniques with mathematical modelling, as a unique approach to build robust mathematictical models for the prediction of drug effects in human, which is the ultimate aim of her research. Specifically, Dr de Lange started groundbreaking work of applying intracerebral microdialysis to the study of drug transport across the blood-brain barrier (BBB), developing new insights in the role of transporters at the BBB and within the CNS, as well as the impact of (disease) conditions on CNS drug distribution. Within the last years, her initial research focus on the CNS has expanded to other body tissues (gut) and fluids (blood clotting), as well as to generic pharmacological problems.
Her program focuses on the development of general translational Pharmacokinetic (PK)- Pharmacodynamic (PD) disease progression (DP) models using advanced in vivo animal experimentation, analytical techniques and mathematical modeling approaches. It involves identification and characterization of the rate and extent of key factors in PK and PKPD relationships and their condition dependency. These key factors involve the kinetics of the drug in plasma; passive and active drug transport into and out of the target tissue; drug distribution within the target tissue; drug equilibration to the target site; and the ability of the drug to interact with the target, in conjunction with biomarkers of disease and effect. Particular emphasis lies on but is not restricted to the Central Nervous System (CNS), and the role of drug-target interactions in the relationship between dose and effect profiles.
This research has a comparative and integrative design to elucidate conditional influences on individual mechanisms. It includes the cycle of simulations – predictions – experimental testing – data modeling– simulations, etc. Experiments typically involve monitoring techniques in (freely moving) chronically instrumented animals, including microdialysis. The microdialysis technique enables to monitor free drug concentrations in a selected tissue, which is an indispensable tool in characterizing rate and extent of passive and active drug dsitribution parameters, and is most valuable to reveal active concentrations at the target site. Moreover, the microdialysis technique can be used to monitor biomarker kinetics.
Such techniques are applied in healthy animals, as well as in models of Alzheimer’s disease, Parkinson’s disease and Epilepsy in which disease progression plays a role. The final emphasis is on translation of models to the human situation, and to validate the model predictions by actually observed human (clinical) data.
The final emphasis is on translation of models to the human situation, and to validate the model predictions by actually observed human (clinical) data.
研究兴趣
论文共 263 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (2024): 106736-106736
European Journal of Pharmaceutical Sciencespp.106736-106736, (2024)
CNS Drugsno. 5 (2024): 1-25
DRUG METABOLISM REVIEWSno. 1 (2024): 1-30
European Journal of Pharmaceutical Sciences (2023): 106345-106345
Pharmaceutical researchno. 11 (2023): 2555-2566
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (2023): 106462-106462
bioRxiv (Cold Spring Harbor Laboratory) (2023)
International journal of molecular sciencesno. 5 (2023): 4960-4960
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn